Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
500
Trial Sponsor
Clinical Trial Start Date
2010
0Primary Completion Date
2011
0Study Completion Date
2011
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Interventional Trial Phase
Phase 10
Official Name
A Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating Pharmacokinetics and Safety of a Human Monoclonal Antibody (AVP-21D9) in Normal Healthy Volunteers0
Last Updated
November 22, 2012
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Double0
Masked Party
Care Provider0
Participant0
Other attributes
Intervention Treatment
AVP-21D90
Placebo0
Study summary
Primary: • To compare the safety profile of a single intravenous administration of AVP-21D9 as compared with Placebo Secondary: * To evaluate the pharmacokinetics (PK) of a single intravenous administration of AVP-21D9 * To evaluate the immunogenicity of AVP-21D9
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
